Why EverydayMeds for Your Weight Management Choice?
Order Wegovy vs Mounjaro: Understanding Your Options
When you're ready to order Wegovy, understanding how it compares to Mounjaro helps ensure you make the right choice for your weight management journey. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural fullness hormone, whilst Mounjaro contains tirzepatide, which targets both GLP-1 and GIP receptors for a dual-hormone approach. This fundamental difference means both medicines work to reduce appetite and promote satiety, but through slightly different pathways in your body.
The practical implications of choosing to order Wegovy over Mounjaro extend beyond mechanism to real-world convenience factors. Wegovy's dosing schedule involves five escalation steps from 0.25mg to 2.4mg over 16 weeks, whilst Mounjaro uses six steps from 2.5mg to 15mg. For patients who prefer a more gradual approach or have experienced side effects with other treatments, Wegovy's lower starting dose may offer advantages. EverydayMeds stocks both options, ensuring you're not limited by supply constraints that affect many UK pharmacies.
Transparent Pricing When You Order Wegovy or Mounjaro
Understanding costs upfront is crucial when comparing your options to order Wegovy versus Mounjaro. Wegovy pricing at EverydayMeds starts with the 0.25mg starter dose at £79.99, progressing through 0.5mg at £94.99, 1mg at £99.99, 1.7mg at £139.99, and the maintenance 2.4mg dose at £209.99. Our Getting Started bundles, such as the Intro Duo containing both 0.25mg and 0.5mg pens for £169.99, provide convenient first-month coverage. New customers benefit from discount code FIRST40, whilst returning customers use DOSE25, both applied automatically at checkout.
Mounjaro pricing follows a different structure reflecting its distinct dosing schedule, with costs varying across the 2.5mg through 15mg range. When you order Wegovy through EverydayMeds, you're choosing a treatment where the maintenance dose remains constant at 2.4mg once reached, potentially offering more predictable long-term costs. Our bundle options, including the Ultimate Stability Trio providing three months of 2.4mg maintenance doses for £649.99, support patients who've successfully reached their target dose and want supply security.
Clinical Evidence Supporting Your Decision to Order Wegovy
The STEP clinical trial programme provides robust evidence supporting Wegovy's effectiveness for weight management when used alongside a reduced-calorie diet and increased physical activity. In the landmark STEP 1 trial published by Wilding et al. in the New England Journal of Medicine (2021), participants taking Wegovy achieved approximately 15% average weight loss at 68 weeks compared to 2.4% with placebo. STEP 2 demonstrated that patients with type 2 diabetes experienced around 9.6% weight reduction, whilst STEP 3 showed approximately clinically studied weight loss when combined with intensive behavioural therapy.
The recent SELECT cardiovascular outcomes trial adds another dimension for patients considering whether to order Wegovy, demonstrating a 20% reduction in major cardiovascular events (hazard ratio 0.80) in adults with established cardiovascular disease. This evidence supports Wegovy as more than just a weight management tool, potentially offering cardiovascular protection benefits. However, individual results may vary, and your prescriber will assess whether these trial outcomes are relevant to your specific health circumstances and weight management goals.
How Wegovy Works: The GLP-1 Mechanism Explained
When you order Wegovy, you're choosing a treatment that works by mimicking glucagon-like peptide-1 (GLP-1), a hormone naturally produced in your intestines after eating. This hormone signals to your brain that you're full and satisfied, whilst also slowing gastric emptying to help you feel fuller for longer periods. Wegovy's once-weekly injection provides sustained GLP-1 receptor activation, potentially reducing appetite throughout the week and diminishing food cravings between meals. The treatment may help you feel satisfied with smaller portion sizes and reduce the psychological drive to eat, particularly foods high in fat and sugar. This mechanism explains why Wegovy must be used alongside dietary changes and increased physical activity rather than as a standalone solution.
Simple Process to Order Wegovy Through EverydayMeds
Ordering Wegovy through EverydayMeds begins with our comprehensive 3-minute online clinical assessment, designed to gather the essential information our prescribers need to determine suitability. You'll provide details about your current weight, height, previous weight loss attempts, medical history, and any medications you're currently taking. Our GPhC-registered prescribers (pharmacy registration #9012878) then review your assessment, typically within 3 working days for standard service or 24 hours for express review. Once approved, your Wegovy prescription is prepared and dispatched via next-day delivery using specialist cold-chain packaging to maintain the medicine's integrity during transport. The entire process from assessment to delivery typically takes 4-5 days, ensuring you can begin treatment promptly whilst maintaining all necessary safety checks.
Storage Advantages When You Order Wegovy
Wegovy's storage requirements offer practical advantages that many patients find valuable, particularly when comparing options for long-term treatment. Each FlexTouch pre-filled pen must be stored in the refrigerator at 2-8°C before first use, but once removed from refrigeration, Wegovy remains stable for up to 6 weeks at room temperature below 30°C. This extended room temperature stability provides significantly more flexibility than Mounjaro's 21-day room temperature limit, making Wegovy particularly suitable for patients who travel frequently or prefer not to transport refrigerated medications. The pen's intuitive design includes a dose counter and automatic needle insertion, with each pen containing four doses of your prescribed strength for convenient once-weekly administration.
Order Wegovy vs Mounjaro: Making Your Personal Choice
The decision to order Wegovy rather than Mounjaro often comes down to individual factors including your previous treatment experience, side effect tolerance, and lifestyle preferences. Wegovy's single-hormone GLP-1 approach may suit patients who prefer a well-established mechanism with extensive clinical data spanning several years of real-world use. The gradual dose escalation from 0.25mg allows for careful tolerance assessment, whilst the eventual 2.4mg maintenance dose provides a clear target endpoint.
Some patients find Wegovy's storage flexibility particularly appealing, especially if they travel regularly for work or leisure activities where refrigeration isn't consistently available. The 6-week room temperature stability means you can pack Wegovy for extended trips without complex cooling arrangements. EverydayMeds' ability to supply both treatments means your choice isn't constrained by pharmacy limitations, and our clinical team can support you in switching between treatments if your initial choice proves unsuitable.
Start Your Weight Management Journey Today
When you're ready to order Wegovy, EverydayMeds provides the complete service from initial assessment through ongoing supply management. Our discount codes FIRST40 for new customers and DOSE25 for returning customers are automatically applied at checkout, ensuring you receive the most competitive pricing available. The combination of clinical expertise, reliable supply chains, and comprehensive patient support makes EverydayMeds your ideal partner for long-term weight management success. Remember that both Wegovy and Mounjaro require ongoing commitment alongside dietary changes and increased physical activity to achieve optimal results. Visit https://everydaymeds.co.uk/collections/weight-loss to begin your clinical assessment and take the first step toward effective weight management with expert guidance every step of the way.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
